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Extracellular vesicles play a crucial role in intercellular
communication by transmitting biological materials
from donor cells to recipient cells. They have
pathophysiologic roles in cancer metastasis,
neurodegenerative diseases, and inflammation.
Extracellular vesicles also show promise as emerging
therapeutics, with understanding of their physiology
including targeting, distribution, and clearance
therefore becoming an important issue. Here, we
review recent advances in methods for tracking and
imaging extracellular vesicles in vivo and critically
discuss their systemic distribution, targeting, and
kinetics based on up-to-date evidence in the
literature.
Keywords: Extracellular vesicle, Exosome,
Microvesicle, Imaging, In vivo distributionimportant issue for their diagnostic and therapeutic use
[14–16] in cancer [17, 18] and in regenerative medicineBackground
Extracellular vesicles (EVs) released from a variety of
cells target recipient cells for intercellular communica-
tion and transfer a subset of genetic materials and pro-
teins [1–3]. Until now, diverse roles have been identified
for EVs, ranging from immune modulation [4–6], to
neuron–glial communication [7, 8], to stem cell-injured
tissue interaction [9], to the pathophysiological processes
of cancer metastasis [10–12].
EVs include a broad spectrum of vesicles secreted by
several types of cells and the term is used as a collective
one. These include exosomes, ectosomes, oncosomes,
shed vesicles, and microvesicles. Thus, EVs represent a* Correspondence: dsl@plaza.snu.ac.kr
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cells. Among these, exosomes are small (30–100 nm)
vesicles derived from the endosomal pathway while
microvesicles are of various sizes and generated by bud-
ding of the plasma membrane (50–1000 nm) [3, 5].
However, discriminating exosomes from microvesicles
is difficult based on their physical properties or pro-
tein composition. Because of this overlap, we discuss
imaging results and physiology of EVs referring to both
types of EVs.
Genetic materials or proteins conveyed by EVs func-
tionally change the recipient cells [13], and therefore
visualization and tracking of EVs currently receive great
attention as a way to reveal their physiology. Recently
developed imaging techniques provide direct evidence of
cellular phenotypic change as a consequence of intercel-
lular transfer of genetic materials mediated by EVs.
Tracking of exogenous engineered EVs also became an
[19]. EVs can transport genetic materials and proteins,
and thus have potential as a drug carrier [17, 20, 21].
Despite the high expectation of therapeutic potential,
the lack of knowledge of in vivo behavior of EVs is a
major drawback. Noninvasive imaging enables us to
understand the in vivo distribution and the fate of EVs
and to elucidate their targeting capability, and here we
review these imaging approaches and critically discuss
the physiology of EVs revealed by the imaging and track-
ing studies.Tracking methods for extracellular vesicles
Fluorescence labeling
The imaging and tracking strategy for EVs is summarized
in Fig. 1. Direct fluorescence labeling of EVs has been
widely used to investigate in vivo behavior of exogenous
EVs. Fluorescence labeling could provide whole-body im-
ages on highly sensitive optical cameras as well as fluores-
cence microscopic images. Thus, EVs labeled with dyes
can be widely used for microscopic identification of EVsle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Strategy for visualization of EVs. The size of EVs is around 100 nm, which restricts direct imaging with optical microscopy. Recently,
several labeling methods have been developed. Lipophilic fluorescence dye is simple and commonly used to track EVs. Reporter imaging
using fluorescence or bioluminescence combined with transmembrane proteins could provide information more specific to EVs than
direct dye labeling. For clinical application and deep tissue imaging, radionuclide imaging or MRI could be possible using 111In-oxine,
99mTc-HMPAO, and iron oxide nanoparticles. GFP green fluorescent protein
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systemically administered EVs. Lipophilic dyes includ-
ing PKH, DiI, and DiR are commonly used and yield
stable fluorescent signals [11, 18, 22, 23]. The labeling
process is very simple and there is no need to use
genetically modified EVs. This simple imaging tech-
nique revealed the spatiotemporal location of system-
ically injected exogenous EVs in target tumors [18].
However, optical imaging is limited to exogenous EVs
and fluorescent dyes persist in tissues even after the
EVs are degraded. This is because lipid labeling is not
specific for intact EVs and fluorescence might remain
in degraded EVs [16].
To visualize endogenous EVs and track cell-to-cell
communication directly, reporter imaging methods were
introduced. Protein markers of EVs, such as CD63, were
used to design reporter conjugated to fluorescent pro-
teins [6, 12]. Although surface proteins labeled with
fluorescent proteins are widely expressed in EVs, only a
subpopulation of EVs is labeled and the signal intensity
depends on the amount of reporter protein expression
[7, 15]. Alternatively, schemes such as labeling trans-
membrane domains with a biotin–streptavidin system
[16] or using a reporter fused with a palmitoylation sig-
nal [15] were also attempted to track endogenous EVs.
Reporter fluorescence imaging systems are more specific
to EVs than lipophilic dyes. However, they require genet-
ically engineered cells, and whole-body optical imaging
of systemically administered EVs is difficult because of
the low yield of fluorescence-labeled EVs.Bioluminescence reporter system
The bioluminescence reporters are able to unravel the
in vivo behavior of EVs with very high sensitivity. Genetic-
ally engineered bioluminescent proteins (e.g., Gaussia lu-
ciferase combined with transmembrane domains such as
lactadherin) could reveal the spatiotemporal distribution
of EVs in a quantitative manner [16, 24] in small animals
without background autofluorescence. Bioluminescence
imaging overcomes the problem of retained or recirculat-
ing fluorescence signals coming from retained fluores-
cence dyes after EV degradation. However, this system has
the shortcoming that the luminescence signal is attenu-
ated when its location is deep in the internal organs. Fur-
thermore, similar to fluorescence reporter imaging, the
bioluminescent signal depends on the reporter protein ex-
pression [7, 15]. These labeling procedures are compli-
cated compared with those of fluorescence dyes, which
limits the study of the in vivo distribution and fate of EVs
in various cells under different conditions.
Radionuclide and magnetic resonance imaging of
extracellular vesicles
Optical imaging of EVs (either fluorescence or biolumin-
escence) has an intrinsic limitation of signal attenuation
even in small animals, and other noninvasive imaging
methods are necessary for clinical applications. Radio-
nuclide labeling of EVs is one of the options. Similarly to
bioluminescence imaging, a streptavidin reporter com-
bined with transmembrane domains expressed in EVs
was conjugated with 125I-labeled norbiotinamide [25].
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111In-oxine, which appeared quite similar to fluorescence
dye labeling [26]. Although the whereabouts of fluores-
cent dyes released from degraded EV membranes are
unknown, 111In—if freed from the cells (and thus prob-
ably from the EVs)—accumulates in the reticuloendothe-
lial system (RES) of the liver, spleen, and bone marrow
[27]. These methods were used only to evaluate ex vivo
biodistribution, but more recently 99mTc-HMPAO-la-
beled EVs were also tested to obtain whole-body images
using single photon emission computed tomography
(SPECT) [28]. The serial imaging of 99mTc-HMPAO-la-
beled EVs enabled us to understand in vivo kinetics of
EVs quantitatively.
Another approach is to use superparamagnetic iron
oxide nanoparticles for magnetic resonance imaging (MRI)
[29, 30]. Electroporation of exosomes with superparamag-
netic iron oxide nanoparticles produced nanoparticle-laden
exosomes [30]. The disadvantage of this method is also dif-
ficult—a very large amount of EVs should be used because
the signal-to-noise ratio is proportional to the amount of
particles on MRI and quantification. Although these non-
invasive imaging techniques including SPECT, positron
emission tomography (PET), and MRI can show EVs even
in deep organs, for clinical translation they require rela-
tively expansive facilities and—except for MRI—may have
concerns of radiation exposure.
In vivo fate, distribution, and targeting of
extracellular vesicles
In vivo fate of extracellular vesicles
EVs secreted by various types of cells can be found in the
circulation and biological fluids. While a fraction of EVs
are degraded by interactions with recipient cells, they are
also systemically cleared from the circulation. In vivo
clearance studies reveal that EVs are rapidly cleared, so
that the half-life is estimated as approximately 2 min
[24, 25, 31]. After this rapid clearance from the circu-
lation, EVs were slowly cleared from the liver, spleen,
and lungs [24]. Bioluminescence reporters showed shorter
half-lives of EVs in most tissues, including the liver, than
did fluorescence markers [16]. The rapid clearance of EVs
is supposed to be due to the nonspecific interactions of
EVs with blood or endothelial cells, given that EVs have
been stable in vitro in plasma (i.e., without interactions
with cells) and the size of EVs is too large to be permeable
to endothelial cells [17, 32].
EVs accumulate in the liver and lungs within 5 min
after systemic injection [24, 25]. Investigators interpreted
this as the EVs being captured by the RES in the very
early phase of circulation. After being retained in the
RES, EVs might be degraded. The pattern of rapid clear-
ance is very similar to liposomes [33], which are rapidly
cleared by the liver and spleen. Because of the similarityof clearance between liposomes and EVs regardless of
origin [26], differences in surface markers of diverse EVs
were thought to have little influence, if any, on their sys-
temic clearance/excretion, the authenticity or generality
of which is yet to be elucidated.
Reports suggesting rapid RES sequestration of the EVs
raised concerns similar to those of liposome reports. In
the literature on liposomes, investigators used in-house
liposomes and the variability of RES uptake depended
on many physicochemical factors such as size, surface
charge, and composition [34–36]. The clearance of ex-
ogenous EVs mimicked that of liposomes as the propor-
tion of RES uptake of EVs would have been influenced
by the purity and composition of EVs. In addition, EV
degradation is affected by the optimality of EV production.
Both injection of aggregated EVs and immediate aggrega-
tion after systemic injection of EVs resulted in pulmonary
sequestration [28]. However, unlike liposomes, EV pro-
duction from various cell sources requires another step of
purification. This would have resulted in investigation-to-
investigation and batch-to-batch variability. We propose
that during the production of EVs every batch should be
tested for consistency before further investigating the
physiologic roles or the theranostic capability of EVs.
In vivo distribution and tissue targeting
EVs have specific proteins such as integrins that interact
with recipient cells [3], and they were expected to have
the capability of in vivo homing and targeting to specific
receptors. This property promised application of EVs as
therapeutic vehicles for several diseases. For example,
EVs derived from mesenchymal stem cells showed thera-
peutic effects on myocardial or renal injuries by reaching
the damaged target tissues [37–39]. However, several
studies into therapeutic effects of EVs did not show
in vivo distribution of EVs to prove targeting to specific
tissues. Thus, imaging-based studies are needed to deter-
mine the roles of EVs in targeting especially the remote
organs.
Imaging and tracking of EVs could reveal what is hap-
pening to EVs in circulation and whether they are target-
ing specific tissues. Unfortunately, the literature reports
are inconsistent depending on the methods of imaging
and tracking. For instance, subcutaneously injected
melanoma-derived EVs accumulated in the lymph nodes
were regarded as a premetastatic niche in one study
[11]. Another study using bioluminescence imaging re-
ported that their systemically injected melanoma-derived
EVs labeled with 125I-biotin accumulated mostly in the
lungs and spleen [24]. Fluorescence-labeled exosomes
derived from melanoma cells accumulated mainly in the
bone marrow and lungs, which was interpreted as an in-
duced metastatic environment [10]. These studies used
EVs derived from the same type of cells (melanoma), but
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lungs, and bone marrow). As different administration
routes and labeling/tracking methods were used, their
influence on the in vivo distribution results should be
re-examined.
One of the studies revealed that the reason for the differ-
ent results was the labeling methods. Lipophilic fluorescent
dye remained in the tissues even after vesicles were
degraded while bioluminescence reporters did not [16]. In
our preliminary study, simultaneous DiI and 99mTc-
HMPAO labeling showed different distribution patterns
(Fig. 2). In vivo distribution was also affected by the proto-
cols of labeling EVs extracted from labeled donor cells or
labeling after EV purification [40]. EVs labeled with fluores-
cence dye showed higher accumulation in the liver, while
fluorescence-labeled EVs collected from fluorescence-
labeled donor cells showed more specific accumulation in
the injured tissue and less in the liver. These results imply
that both free forms and metabolites of dyes or tracers
from degraded EVs have to be considered in the interpret-
ation. Because each labeling method has its advantages and
limitations, a multimodal approach is encouraged [16].
Multimodal tracking in the specific organs could also help
to understand the in vivo kinetics of EVs.
There is a concern that lung and liver uptake is some-
times interpreted as RES uptake of circulating EVs. RES ac-
cumulation of labeled white blood cells has been well
known. According to textbook knowledge [27], systemicallyFig. 2 Imaging of dual tracer-labeled exosome-mimetic nanovesicles. Exosom
simultaneously. a Ex vivo fluorescence image acquired 3 h after the intraveno
brain. b SPECT images acquired in vivo at 0.5 and 3 h after the intravenous in
from fluorescence imaging, showing that the nanovesicles accumulated
Simultaneous labeling revealed a different distribution which might be
vesicles degraded in their initially retained tissuesadministered autologous white blood cells first migrate to
the lungs and stay there for a short while, and then move
to the inflammation sites or RES tissues including the bone
marrow. Immediate lung uptake of EVs, liposomes, or inor-
ganic nanomaterials is considered to be due to the aggrega-
tion of these materials, which is hardly a physiologic
phenomenon [34, 41]. When preparation of radiolabeling
was suboptimal, EVs also accumulated in the lungs [28].
On the other hand, liver uptake of EVs could be due to he-
patocellular uptake of EVs rather than uptake by the RES
and formation of metabolites may also result in hepatobili-
ary excretion and gastrointestinal tract accumulation. A
recent study showed that the gastrointestinal activity indi-
cated hepatobiliary excretion [42], which varied according
to the routes of administration, cell sources, and most not-
ably the time after administration.
Although in vivo distribution of EVs including organ-
specific accumulation is closely related to systemic func-
tions, biological effects of EVs in target tissues should be
proven as mediators of intercellular communication by
imaging studies. Microscopic imaging studies revealed
that the exchanges of biomaterials mediated by EVs at
the cellular level eventually showed phenotypic changes.
For instance, benign tumor cells, which took up EVs se-
creted by malignant cancer cells, changed their pheno-
types, which were directly visualized by the Cre-LoxP
system with green fluorescent protein [43, 44]. In the fu-
ture, to clarify the physiology of EVs, imaging of EVse-mimetic nanovesicles [14] were labeled with DiI and 99mTc-HMPAO
us injection. Nanovesicles accumulated in the liver, intestine, kidneys, and
jection. In this specific example, the accumulation pattern was different
mainly in the liver and spleen and were few in the intestine.
partially caused by the differences of behavior of tracers after
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as in vivo distribution and tissue targeting of EVs.
Cell type-specific in vivo distribution
The in vivo distribution of EVs depended partly on their
cellular origin. Although distribution study results were
affected by the labeling methods as already described,
cell type specificity, if any, is also important to under-
stand whether EVs have a ‘homing’ capability to recipient
cells. A study of biodistribution as a function of cell
sources was performed using fluorescence dye-labeled
EVs [42]. The size of EVs derived from different sources
(muscle, melanoma, and immature bone marrow) was
similar (around 100 nm) and they accumulated mostly
in the liver and in the spleen. The uptake and clearance
pattern was almost similar despite their different origin
and only the amount of uptake was slightly different.
Another study using both fluorescence dye and 111In-
oxine labeling detected that EVs of different cell origins
had similar distribution patterns, which also showed ac-
cumulation mainly in the RES. Liposomes with similar
size and exosome-mimicking liposomes (liposomes syn-
thesized from lipid extracts of exosomes) showed similar
distribution in this report [26].
Studies of tumor targeting or inflammatory tissue tar-
geting by EVs produced inconsistent results. Tumor
characteristics or inflammation could affect the in vivo
distribution by influencing the homing behavior of EVs.
Exosomal membrane fused with specific integrin recep-
tor ligand such as RGD peptide showed a possibility of
tumor-specific accumulation of EVs using fluorescence
imaging [45]. The surface-modified EVs were accumu-
lated more in the tumor than in the liver or spleen.
Ohno et al. used fluorescence-labeled EVs to target epi-
dermal growth factor receptor-positive breast cancer
cells and showed tumor accumulation, although the de-
gree of accumulation was much less than in the liver
and spleen [18]. Another study using exosome-mimetic
nanovesicles derived from macrophages without surface
modification indicated that they were distributed prom-
inently in the tumor [14]. However, another study found
that tumor accumulation of EVs was minimal just like li-
posomes [26]. Approximately 3 % of EVs derived from
human embryonic kidney cell lines accumulated in the
tumor tissues nonspecifically, which could be due to en-
hanced permeation and retention of EVs [42]. Mesen-
chymal stem cell-derived EVs tended to accumulate in
the injured tissues, although they also accumulated in
the liver and spleen [40]. The underlying mechanism of
tumor accumulation of EVs remains unknown. A num-
ber of in vivo studies did not compare the distribution
of EVs with that of liposomes as controls. Because the
cellular uptake of EVs is greater than that of liposomes
in vitro in specific cells, and uptake is dependent on therecipient cell types [46], a comparison with liposomes of
similar size will be needed to elucidate the active target-
ing capabilities of EVs.
To sum up, EVs of similar sizes were cleared by the
RES and mainly accumulated in the liver, spleen, and
lungs, while protein and lipid components that vary by
cellular origin have a minor effect to change the gross
accumulation and clearance patterns of EVs from the
target tissues. Although tumor or inflammatory tissues
may affect the accumulation pattern, in most studies the
uptake of EVs by the liver and spleen is attributed to
RES clearance. It is not directly evident whether accu-
mulation of EVs in tumor or injured tissues is mediated
by active targeting or enhanced permeation and retention,
or both. For now, the in vivo EV distribution reports imply
that the intercellular communication mediated by EVs
mostly takes place between neighboring cells rather than
the donor cells and the distant targets, which might be
limited by RES clearance and/or hepatocellular excretion.
Extracellular vesicles for brain delivery
Among the issues of in vivo distribution, it is unique
and important to understand whether extraneous EVs
are transferred to the brain. To use EVs as possible ther-
apeutics for brain disorders, understanding the in vivo
distribution of brain-targeted EVs is imperative. In gen-
eral, delivery of nano-sized vesicles to the brain has been
considered to be restricted because of the blood–brain
barrier (BBB). Systemically injected luciferase-labeled
EVs were minimally found in the brain tissue regardless
of cell types [16, 24]. Radionuclide-labeled EVs indicated
almost no accumulation in the brain tissue when EVs
were systemically administered [25]. As mentioned pre-
viously, most extraneous EVs are captured in the liver
and spleen or in the lungs [24], which could also hamper
the targeted delivery to the brain as well as to other
organs or target tissues. These findings suggest, so far,
that the intercellular communication using EVs across
the BBB might hardly take place.
Nevertheless, therapeutic application has been attempted
in small animals using enhanced brain delivery of EVs.
Alvarez-Erviti et al. [20] engineered EVs to carry rabies
viral glycoprotein (RVG) and showed their therapeutic po-
tential as a small interfering RNA (siRNA) transporter to
cross the BBB to treat Alzheimer’s disease in mice. RVG
modification of EVs enhanced brain accumulation about
twofold compared with nonmodified EVs [42], although
brain accumulation was much less (1–2 %) than in the liver
and spleen (70–80 %).
Intranasal delivery of EVs, another promising adminis-
tration route to the brain, was also tried [47, 48]. Direct
delivery of stem cells via the nasal route resulted in cells
spilling to the lungs, which later caused tumors [49].
Intranasal delivery of inorganic nanoparticles or
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nucleic acids is not easy because they are unstable in
the extracellular milieu, and thus exosomal packaging
of therapeutic RNAs or peptides might prove better. In
the future, just like other nanovesicles [50], engineered
EVs to target the brain via the best route of brain delivery,
such as the nasal route, should promote therapeutic appli-
cations of EVs.
Conclusion
Imaging of EVs is essential to understand the physi-
ology of EVs and to apply EVs as therapeutics for vari-
ous diseases. The simple and commonly used tracking
is carried out with lipophilic labeling of EVs either
using fluorescent dyes or radiolabeled dyes. However,
accurate tracking of EVs was limited due to nonspecifi-
city of labeling and retention or recirculation of labels
after degradation. Furthermore, optical imaging has the
issues of limited penetration depth and potential tox-
icity of substrates in the case of luciferin. In the future,
for clinical application of EVs, radionuclide imaging
and MRI may be used as noninvasive imaging methods
without these disadvantages.
Even though distinctive roles of EVs for intercellular
communication are mediated by the complex and spe-
cific composition of EV lipids and proteins, systemic
distribution and clearance did not yet disclose the differ-
ences according to the EV origins and compositions. In
vivo distribution of EVs appears to be similar to artificial
nanovesicles such as liposomes. EVs are rapidly cleared
by the RES or excreted via the liver or kidneys, which
may limit their reach to certain target tissues; surface
modification to reduce nonspecific uptake may also be
required for eventual clinical application of EVs as
therapeutics.
Studies of the secretion of EVs by various cells under
diverse conditions suggest that there are many subsets
of EVs composed of different genetic materials and pro-
teins including surface markers and other biomaterials
[52, 53]. If we wish to make a library of EVs of interest,
including their roles in physiology and their future
therapeutic potential, information regarding their in vivo
distribution, clearance, and kinetics should be noted for
each subtype of EVs. To elucidate the physiology of
various subsets of EVs, novel methods of isolation and
purification of these subsets as well as efficient methods
for their in vivo characterization will be needed to
understand intercellular communication between EV
donor cells and receptor cells or distant organs.
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